Program
Minoxidil
Also written as “Minoxidil Tablets”, “minoxidil + finasteride” and “5% minoxidil foam”.
Its studies are mostly in Alopecia · Hypotrichosis, led by 9 companies.
Drug pageMinoxidil: every studyMany companies study it; this page follows only the 13 they lead. All 40 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Aneira Pharmaits history only | 21 open or running | phase 1since May 8, 2023 | Mar 17, 2023 | none ahead |
| Galderma Groupits history only | 20 open or running | no phasesince May 29, 2015 | May 29, 2015 | none ahead |
| Industrial Farmacéutica Cantabriaits history only | 21 open or running | phase 3since May 25, 2023 | May 25, 2023 | none ahead |
| Johnson & Johnsonits history only | 20 open or running | phase 3since Sep 8, 2005 | Sep 8, 2005 | none ahead |
| 3SBioits history only | 10 open or running | phase 3since Jul 15, 2025 | Jul 15, 2025 | none ahead |
| Beijing Dayspring Pharmaceutical Technologyits history only | 10 open or running | phase 2since Jul 1, 2025 | Jul 1, 2025 | none ahead |
| Eurofarma Laboratoriosits history only | 11 open or running | phase 3since Apr 8, 2026 | Apr 8, 2026 | Oct 30, 2028phase 3 · NCT07529977 |
| Maja Kovacevic, MDits history only | 10 open or running | no phasesince Jun 25, 2015 | Jun 25, 2015 | none ahead |
| Samson Clinical Operations Ptyits history only | 10 open or running | phase 3since Apr 6, 2025 | Apr 6, 2025 | none ahead |
Also a collaborator on its studies: Bioskin and Astrum CRO, S.L.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 8, 2005First study: phase 3 study in AlopeciaNew to Johnson & JohnsonJohnson & Johnson · NCT00151515 · 352 enrolled · United States
- Jun 15, 2010Phase 3 study in AlopeciaJohnson & Johnson · NCT01145625 · 322 enrolled · United States, Canada, France and more
- May 29, 2015Galderma Group’s first studies: 2 no phase studies in AlopeciaNew to Galderma GroupGalderma Group · NCT02460497, NCT02460289
- Jun 25, 2015Maja Kovacevic, MD’s first study: no phase study in AlopeciaNew to Maja Kovacevic, MDMaja Kovacevic, MD · NCT02486848 · Italy
- Mar 17, 2023Aneira Pharma’s first study: early phase 1 study in HypotrichosisNew to Aneira PharmaAneira Pharma · NCT05790941 · 12 enrolled · United States
- May 8, 2023Phase 1 study in AlopeciaAneira Pharma · NCT05864885 · 14 planned
- May 25, 2023Industrial Farmacéutica Cantabria’s first study: phase 3 study in AlopeciaNew to Industrial Farmacéutica CantabriaIndustrial Farmacéutica Cantabria · NCT05888922 · 520 enrolled · Germany, Italy, Portugal and more
- May 31, 2023Phase 1 study in HealthyIndustrial Farmacéutica Cantabria · NCT06015516 · 14 enrolled · Spain
- Apr 6, 2025Samson Clinical Operations Pty’s first study: phase 3 study in AlopeciaNew to Samson Clinical Operations PtySamson Clinical Operations Pty · NCT06924632 · 142 enrolled · Australia
- Jul 1, 2025Beijing Dayspring Pharmaceutical Technology’s first study: phase 2 study in AlopeciaNew to Beijing Dayspring Pharmaceutical TechnologyBeijing Dayspring Pharmaceutical Technology · NCT07076706 · 110 enrolled · China
- Jul 15, 20253SBio’s first study: phase 3 study in AlopeciaNew to 3SBio3SBio · NCT07080931 · 296 enrolled · China
- Apr 8, 2026Eurofarma Laboratorios’ first study: phase 3 study in AlopeciaNew to Eurofarma LaboratoriosEurofarma Laboratorios · NCT07529977 · 372 planned · Brazil
Ahead
- Oct 30, 2028Primary completion: phase 3 study in AlopeciaEurofarma Laboratorios · NCT07529977
TargetBeta
“Sulfonylurea receptor 2, Kir6.2 opener”ChEMBL 37, by rule
Studies
All 13 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07529977Alopecia · Brazil | 3 | Not yet recruiting | Eurofarma Laboratorios | Oct 30, 2028 | 372 |
| NCT07080931Alopecia · China | 3 | Completed | 3SBio | Jun 6, 2026 | 296 |
| NCT07076706Alopecia · China | 2 | Completed | Beijing Dayspring Pharmaceutical Technology | Aug 26, 2025 | 110 |
| NCT06924632Alopecia · Australia | 3 | Completed | Samson Clinical Operations Pty | May 15, 2026 | 142 |
| NCT06015516Healthy · Spain | 1 | Completed | Industrial Farmacéutica Cantabria | Mar 8, 2024 | 14 |
| NCT05888922Alopecia · Germany, Italy, Portugal and more | 3 | Active, not recruiting | Industrial Farmacéutica Cantabria | Oct 2026 | 520 |
| NCT05864885Alopecia | 1 | Not yet recruiting | Aneira Pharma | Jul 17, 2023 | 14 |
| NCT05790941Hypotrichosis · United States | Early 1 | UNKNOWN | Aneira Pharma | Jun 30, 2023 | 12 |
| NCT02486848Alopecia · Italy | – | Withdrawn | Maja Kovacevic, MD | Dec 2016 | 0 |
| NCT02460497Alopecia · United States | – | Completed | Galderma Group | Sep 19, 2015 | 61 |
| NCT02460289Alopecia · United States | – | Completed | Galderma Group | Nov 2015 | 63 |
| NCT01145625Alopecia · United States, Canada, France and more | 3 | Completed | Johnson & Johnson | Feb 2012 | 322 |
| NCT00151515Alopecia · United States | 3 | Completed | Johnson & Johnson | Jul 2004 | 352 |
How it is read
Names in the registry
- “Minoxidil Tablets”, 2 entries
- “Minoxidil”, 2 entries
- “minoxidil + finasteride”, 2 entries
- “5% minoxidil foam”, 1 entry
- “Minoxidil oral solution”, 1 entry
Conditions, from the studies’ own filings
- Alopecia, 11 studies
- Hypotrichosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.